𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prognostic significance of HER-2/neu gene amplification status by fluorescence in Situ hybridization of prostate carcinoma

✍ Scribed by Jeffrey S. Ross; Christine E. Sheehan; Alida M. Hayner-Buchan; Robert A. Ambros; Bhaskar V. S. Kallakury; Ronald P. Kaufman Jr.; Hugh A. G. Fisher; Matthew D. Rifkin; Patrick J. Muraca

Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
503 KB
Volume
79
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

in breast carcinoma and other cancers

📜 SIMILAR VOLUMES

HER-2/neu amplification by fluorescence
HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma
✍ Bozzetti, Cecilia ;Personeni, Nicola ;Nizzoli, Rita ;Guazzi, Annamaria ;Flora, M 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB

BACKGROUND. Amplification of the HER-2/neu oncogene has been proposed as a target for antibody-based therapies and as a predictor of chemoresponsiveness in advanced breast carcinoma. Few studies have concentrated on HER-2/neu gene evaluation by fluorescence in situ hybridization (FISH) on distant me

HER-2/NEU gene amplification in breast i
HER-2/NEU gene amplification in breast imprint cytology analyzed by fluorescence in situ hybridization: Direct comparison with companion tissue sections
✍ Jeffrey G. Moore; Viet To; Shobha J. Patel; Nour Sneige 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 203 KB 👁 2 views

Fluorescence in situ hybridization (FISH) is a validated method for detection of HER-2/neu gene amplification and was recently approved by the FDA for diagnostic use in paraffin-embedded tissue. Its use in cytologic specimens, however, has not been investigated. To see whether HER-2/neu gene amplifi

Comparison of HER-2 status determined by
Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma
✍ Yun Gong; Daniel J. Booser; Nour Sneige 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB

## Abstract ## BACKGROUND Accurate assessment of __HER‐2__ status is necessary prior to anti‐__HER‐2__ antibody (trastuzumab) therapy for metastatic breast carcinoma. However, controversy exists regarding whether to assess __HER‐2__ status in the primary tumor or in metastatic lesions. It is also

A comparison of five immunohistochemical
A comparison of five immunohistochemical biomarkers and HER-2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma
✍ Doo Ho Choi; Dong Bok Shin; Min Hyuk Lee; Dong Wha Lee; Devika Dhandapani; Darry 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 1 views

## Abstract ## BACKGROUND The objective of this article was to compare five tumor markers between white women in the U.S. and native Korean women with early‐onset breast carcinoma. ## METHODS Sixty Korean women who were diagnosed with breast carcinoma at age 45 years or younger and 60 white wome

Detection of Her-2/neu oncogene in breas
Detection of Her-2/neu oncogene in breast carcinoma by chromogenic in situ hybridization in cytologic specimens
✍ Fan Lin; Ting Shen; Jeffrey W. Prichard, 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB

Determination of Her-2/neu oncogene amplification is important in the current treatment of breast carcinoma. In addition to fluorescence in situ hybridization (FISH) and immunohistochemical stain (HercepTest 1 ), chromogenic in situ hybridization (CISH) has been shown to be a sensitive and specific

Fluorescence in situ hybridization gene
Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib
✍ Laura Vidal; Ming S. Tsao; Gregory R. Pond; Ezra E. W. Cohen; Roger B. Cohen; Er 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 190 KB

## Abstract ## __Background.__ Gene amplification status of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2) were analyzed and correlated with clinical outcome in patients with progressive malignant salivary glands tumors (MSGT) treated with the d